PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Innovative Marketing Techniques Focusing on Product Quality and Efficacy Features - New analysis from Frost & Sullivan, U.S. Nebulizers Markets, reveals that revenue in this market totaled $ 116.1 million in 2004 and is projected to grow to $147.6 million by 2011.
Innovative Marketing Techniques Focusing on Product Quality and Efficacy Features

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2005/09/28 - New analysis from Frost & Sullivan, U.S. Nebulizers Markets, reveals that revenue in this market totaled $ 116.1 million in 2004 and is projected to grow to $147.6 million by 2011. .

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The crowded drug pipeline for asthma treatments is an indication of the unmet needs of asthma patients in the United States. With the development of more efficient and sophisticated drug formulations, physicians, healthcare professionals, and patients have access to a wider variety of nebulizer solutions. Because of the highly competitive market, end users evaluate products largely by their cost, thus leading to a “commodity trend” where price is the only differentiating factor among products.

In order to change this ‘commodity trend’ where-in competition is primarily based on price, nebulizer manufacturers need to differentiate products based on quality and features by thoroughly educating patients, physicians and homecare providers.

New analysis from Frost & Sullivan (medicaldevices.frost.com), U.S. Nebulizers Markets, reveals that revenue in this market totaled $ 116.1 million in 2004 and is projected to grow to $147.6 million by 2011.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Nebulizers Markets, send an e-mail to Melina Gonzalez, Corporate Communications, at melina.gonzalez[.]frost.com with the following information: your full name, company name, title, telephone number, fax number, and e-mail address. Upon receipt of the above information, an overview will be sent to you by e-mail.

Increasing end-user education can also help simplify nebulizer technology and product usage. Due to multiple technologies and features, modern nebulizers are more complex. Patients usually do not know the importance of technical details such as droplets size and mechanical specificity that are required for precise drug delivery.

“The medications used with the nebulizers are under scrutiny and the joint commission on accreditation of healthcare organizations and the U.S. food and drug administration (FDA) have both issued recommendations to discontinue use of multi-dose bottled medications,” notes Frost & Sullivan Research Analyst Navendu Bhatt. “By using sterile, pre-measured, and pre-mixed unit-dose medications, it is possible to eliminate possible dosing errors and reduce nosocomial infections originating from hospital-like settings.”

Tubes form a standard part of nebulizer apparatus, and patients are thereby at an increased risk of being contaminated by air-born pathogens. Nebulizers depend on controlled breathing to deliver medication and the use of masks along with the nebulizers can help minimize such contamination risks.
Nebulizers have entered a market that has the presence of well-established competing technologies such as meter dose inhalers (MDIs) and dry powder inhalers (DPIs). While the late entry may slow penetration, this scenario could change once more products are introduced and physicians and patients gain confidence.

The number of patients with conditions treated by approved drug combinations delivered through nebulizers has continued to increase. While the increase in incidence and diagnosis of asthma and chronic obstructive pulmonary disease (COPD) is contributing to the rise in demand for nebulizers, they are also finding acceptance in new application for the treatment of conditions, such as diabetes, cancer, and migraine.

The U.S. nebulizers market is witnessing increased competition with the entry of overseas manufacturers. While this is leading to volatile prices, some manufacturers have established production facilities in Asia and South America to avail of lower labor and manufacturing costs.

“Competition is likely to even out and prices are expected to stabilize by 2006-2007,” says Bhatt. “While this may result in increased volumes and better revenues, future growth is likely to stem from the growing popularity of portable compressor nebulizers.”

U.S. Nebulizers Markets, part of the Medical Device subscription, analyses the U.S. market for nebulizer technologies such as conventional compressor, portable compressor, and ultrasonic. It provides manufacturers with key insights into drivers, restraints, and market opportunities. It further profiles emerging technologies and forecasts trends and growth across individual market segments, such as conventional compressor, portable compressor, and ultrasonic nebulizers. Analyst interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

U.S. Nebulizers Markets
A701

Contact

Katja Feick
Corporate Communications – Europe
P: +44 (0) 20 7915 7856
F: +44 (0) 20 7730 3343
E: katja.feick[.]frost.com

Radhika Menon Theodore
Corporate Communications – Asia Pacific
P: +91 44 24314263 Ext: 312
E: rmtheodore[.]frost.com

Surbhi Dedhia
Corporate Communications – India
P: +91 22 2832 4705 Ext: 131
E: sdedhia[.]frost.com

Keywords in this release: nebulizers, U.S., compressor nebulizers, portable handheld compressor nebulizers, ultrasound nebulizers, asthma, chronic obstructive pulmonary disease, COPD, cancer, diabetes, migraine, meter dose inhaler, MDI, dry powder inhaler, DPI, research, information, market, trends, technology, service, forecast, market share

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Innovative Marketing Techniques Focusing on Product Quality and Efficacy Features

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Danielle White 
210.247.2403 dwhite[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)